DOCSLIB.ORG

Computational Docking Study of P7 Ion Channel from HCV Genotype 3 and Genotype 4 and Its Interaction with Natural Compounds

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Computational Docking Study of P7 Ion Channel from HCV Genotype 3 and Genotype 4 and Its Interaction with Natural Compounds See discussions, stats, and author profiles for this publication at: http://www.researchgate.net/publication/278560196 Computational Docking Study of p7 Ion Channel from HCV Genotype 3 and Genotype 4 and Its Interaction with Natural Compounds ARTICLE in PLOS ONE · JANUARY 2015 Impact Factor: 3.53 · DOI: 10.1371/journal.pone.0126510 DOWNLOADS VIEWS 27 11 9 AUTHORS, INCLUDING: Shilu Mathew Kaneez Fatima King Abdulaziz University IQ Institute of Infection and Immunity 16 PUBLICATIONS 3 CITATIONS 26 PUBLICATIONS 77 CITATIONS SEE PROFILE SEE PROFILE Ghazi Damanhouri Ishtiaq Qadri King Abdulaziz University King Abdulaziz University 57 PUBLICATIONS 213 CITATIONS 116 PUBLICATIONS 1,593 CITATIONS SEE PROFILE SEE PROFILE Available from: Ishtiaq Qadri Retrieved on: 05 July 2015 RESEARCH ARTICLE Computational Docking Study of p7 Ion Channel from HCV Genotype 3 and Genotype 4 and Its Interaction with Natural Compounds Shilu Mathew1,2,3, Kaneez Fatima4, M. Qaiser Fatmi5, Govindaraju Archunan3, Muhammad Ilyas6, Nargis Begum1, Esam Azhar7, Ghazi Damanhouri7, Ishtiaq Qadri7* 1 Department of Biotechnology, Jamal Mohamed College, Tiruchirappalli, India, 2 Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia, 3 Department of Animal Science, Bharathidasan University, Tiruchirappalli, India, 4 IQ Institute of Infection and Immunity, Lahore, Punjab, Pakistan, 5 Department of Biosciences, COMSATS Institute of Information Technology, Park Road, Chak Shahzad, Islamabad, Pakistan, 6 Department of Botany, Jamal Mohamed College, Tiruchirappalli, Tamil Nadu, India, 7 King Fahd Medical Research Center, King Abdul Aziz University, Jeddah, Saudi Arabia * [email protected] Abstract OPEN ACCESS Citation: Mathew S, Fatima K, Fatmi MQ, Archunan G, Ilyas M, Begum N, et al. (2015) Computational Background Docking Study of p7 Ion Channel from HCV Genotype 3 and Genotype 4 and Its Interaction with The current standard care therapy for hepatitis C virus (HCV) infection consists of two re- Natural Compounds. PLoS ONE 10(6): e0126510. gimes, namely interferon-based and interferon-free treatments. The treatment through the doi:10.1371/journal.pone.0126510 combination of ribavirin and pegylated interferon is expensive, only mildly effective, and is Academic Editor: Shama Ahmad, University of associated with severe side effects. In 2011, two direct-acting antiviral (DAA) drugs, boce- Alabama at Birmingham, UNITED STATES previr and telaprevir, were licensed that have shown enhanced sustained virologic re- Received: December 8, 2014 sponse (SVR) in phase III clinical trial, however, these interferon-free treatments are more Accepted: April 2, 2015 sensitive to HCV genotype 1 infection. The variable nature of HCV, and the limited number of inhibitors developed thus aim in expanding the repertoire of available drug targets, result- Published: June 1, 2015 ing in targeting the virus assembly therapeutically. Copyright: © 2015 Mathew et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits Aim unrestricted use, distribution, and reproduction in any medium, provided the original author and source are We conducted this study to predict the 3D structure of the p7 protein from the HCV geno- credited. types 3 and 4. Approximately 63 amino acid residues encoded in HCV render this channel Data Availability Statement: All relevant data are sensitive to inhibitors, making p7 a promising target for novel therapies. HCV p7 protein within the paper and its Supporting Information files. forms a small membrane known as viroporin, and is essential for effective self-assembly of Funding: Financial support of this work was provided large channels that conduct cation assembly and discharge infectious virion particles. by the King Abdulaziz City for Science and Technology, (KACST)-Large grant 162-34, to Ishtiaq Qadri. Method Competing Interests: The authors have declared In this study, we screened drugs and flavonoids known to disrupt translation and production that no competing interests exist. of HCV proteins, targeted against the active site of p7 residues of HCV genotype 3 (GT3) PLOS ONE | DOI:10.1371/journal.pone.0126510 June 1, 2015 1/26 Computational Docking Study of HCVp7 Ion Channel from Genotype 3 and 4 (isolatek3a) and HCV genotype 4a (GT4) (isolateED43). Furthermore, we conducted a quantitative structure–activity relationship and docking interaction study. Results The drug NB-DNJ formed the highest number of hydrogen bond interactions with both mod- eled p7 proteins with high interaction energy, followed by BIT225. A flavonoid screen dem- onstrated that Epigallocatechin gallate (EGCG), nobiletin, and quercetin, have more binding modes in GT3 than in GT4. Thus, the predicted p7 protein molecule of HCV from GT3 and GT4 provides a general avenue to target structure-based antiviral compounds. Conclusions We hypothesize that the inhibitors of viral p7 identified in this screen may be a new class of potent agents, but further confirmation in vitro and in vivo is essential. This structure-guided drug design for both GT3 and GT4 can lead to the identification of drug-like natural com- pounds, confirming p7 as a new target in the rapidly increasing era of HCV. Introduction Hepatitis C virus (HCV) is chronically affecting approximately 180 million people worldwide. HCV infected individuals are at risk for liver cirrhosis as well as hepatocellular carcinoma [1, 2]. The enveloped HCV belongs to family Flaviviridae with seven main genotypes and roughly about 100 subtypes according to the wide geographical distribution of the HCV [3, 4]. HCV ge- notypes (GTs) 1–3 are distributed worldwide. The most common subtypes are 1a and 1b, ac- counting for about 60% of global HCV infections. These HCV subtypes prevail in Eastern Europe, Japan, and North America. GT2 remains less frequently reported than GT1. GT3 is en- demic in Southeast Asia, and is unevenly distributed in various other countries around the world. GT4 is largely found in the Middle East, Central Africa, and Egypt, GT5 is almost exclu- sively found in South Africa, and GTs 6–11 are scattered across Asia [5–8]. The current treat- ment routes are limited to interferon-based and interferon-free regimens. Ribavirin and IFN- alpha-2 combination therapy has limited, but variable, effectiveness, depending on the HCV genotype and the host immune response [9, 10]. In the USA, simeprevir, an FDA approved NS3/4A protease inhibitor, is also dosed along with peg-IFN and ribavirin as triple therapy. Re- cently in 2011, Food and Drug Administration (FDA) and European Medicines Agency (EMEA) have approved two direct-acting antivirals (DAAs) namely boceprevir and telaprevir; these NS3/4A protease inhibitors have shown promising sustained virologic response (SVR) in phase III clinical trial, however, they are genotype specific [11]. Some combination therapies of some oral drugs have been also licensed by FDA during 2013 and 2014, which include sofosbu- vir, a nucleotide analog that inhibits RNA polymerase, in combination with ribavirin for oral dual therapy of HCV GT2 and GT3 as well as sofosbuvir in combination with the viral NS5A inhibitor ledipasvir for the treatment of GT1 infection, respectively [12]. During 2012, at least 30 additional DAAs were in various stages of clinical development. The HCV genome is expressed as large as a polyprotein and cleaved by proteases into an array of proteins. The single-stranded RNA genome encodes structural proteins, including core, glycoproteins E1 and E2, and p7, along with non-structural proteins NS2, NS3, NS4A, NS4B, NS5A, and NS5B [13]. The p7 ion channel is positioned in the middle of both the PLOS ONE | DOI:10.1371/journal.pone.0126510 June 1, 2015 2/26 Computational Docking Study of HCVp7 Ion Channel from Genotype 3 and 4 structural protein E2 and non-structural proteins [14]. HCV p7 is a viral channel-forming pro- tein comprised of two elongated hydrophobic transmembrane (TM) domains linked by a cyto- solic loop [15]. However, the structural information for p7 ion channel is known, including protein oligomerization as well as folding of the helices [16, 17]. The hexameric bundle struc- ture was reported for the first time in a Nuclear Magnetic Resonance (NMR) spectroscopic study; the three-dimensional structure of the hexamer was generated using computational methods [18]. The recent advances in computational techniques have enabled us to build small protein molecules and portions of larger protein molecules with reasonably good resolution. Various approaches have been developed and adopted, including a combination of modeling, molecular docking, and molecular dynamics simulations [19]. Computer-modeling of proteins is guided by the knowledge of how membrane proteins are folded or inserted into the lipid membrane. Membrane proteins are translated with the aid of translocons [20–22]. Translocons are membrane-spanning proteins that enable the primary sequence of the membrane protein to form secondary structure within the hydrophobic region of the lipid membrane. The final topology of the membrane protein is dictated by the prime amino acid sequence of the protein [23–25]. The protein is finally released into lipid bilayer. Thus, once the secondary structure is formed, the protein retains this folded structure. These viral channel-forming proteins can also be built alone using computational techniques [26, 27]. Apart from forming a self-assembled, sophisticated, funnel-like architecture that
Load more

Recommended publications
  • Abstract Book Towards an HIV Cure Symposium, 2013 Towards an HIV Cure Symposium 2013 Abstract Book 2
    Abstract Book Towards an HIV Cure Symposium, 2013 Towards an HIV Cure Symposium 2013 Abstract Book 2 Contents Oral Abstract Session 1 4 OA1-1 4 OA1-2 5 OA1-3 6 OA1-4 LB 7 OA1-5 LB 8 Oral Abstract Session 2 9 OA2-1 9 OA2-2 10 OA2-3 11 OA2-4 12 OA2-5 LB 13 OA2-6 LB 14 OA2-7 LB 15 Oral Abstract Session 3 16 OA3-1 16 OA3-2 17 OA3-3 18 OA3-4 LB 19 Oral Abstract Session 4 20 OA4-1 20 OA4-2 22 OA4-3 LB 24 OA4-4 LB 25 Poster Exhibition 26 A5 – Entry (attachment, receptors and co-receptors, penetration and tropism) 26 A8 – Regulation of viral gene expression and replication 27 A9 – Cellular factors necessary for HIV replication 28 A10 – Cellular and tissue reservoirs 31 A11 – Mechanisms of HIV persistence 36 A13 – Strategies to target and eradicate reservoirs 37 A14 – Mucosal transmission 43 A19 – Intrinsic cellular defenses and restriction factors 44 A20 – IFN-I (viral inhibition, immunomodulatory functions) 46 Back to Content page Towards an HIV Cure Symposium 2013 Abstract Book 3 A21 – NK cells and dendritic cells 47 A22 – Monocytes and macrophages 49 A24 – Antibody diversity and function 51 A27 – Cellular immunity 53 A28 – Mucosal immunity 56 A29 – Viral determinants of pathogenesis 57 A30 – Acute and early HIV/SIV infection 58 A41 – Elite controllers 59 A44 – Highly exposed seronegative individuals (HESN) 61 A45 – Correlates of protection 62 A46 – HIV drug development 63 A47 – Mechanisms of anti-retroviral drug resistance 65 A49 – Nucleic acid based HIV and SIV therapy development 67 A50 – Design of approaches targeting inflammation/immune
    [Show full text]
  • Models for Predicting Effective HIV Chemoprevention in Women
    NIH Public Access Author Manuscript J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 April 01. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: J Acquir Immune Defic Syndr. 2015 April 1; 68(4): 369–376. doi:10.1097/QAI.0000000000000472. Models for Predicting Effective HIV Chemoprevention in Women Melanie R. Nicol, PharmD, PhD1,*, Cindi W. Emerson, B.S., B.A.1,2, Heather M.A. Prince, MPA2,3, Julie A.E. Nelson, PhD2,3, Yuri Fedoriw, MD3, Craig Sykes, M.S.1,2, Elizabeth J Geller, MD3, Kristine B. Patterson, MD3, Myron S Cohen, MD2,3, and Angela D.M. Kashuba, BScPhm, PharmD1,2,3 1Eshelman School of Pharmacy, University of North Carolina at Chapel Hill 2Center for AIDS Research, University of North Carolina at Chapel Hill 3School of Medicine, University of North Carolina at Chapel Hill Abstract Objective—Model systems which rapidly identify tissue drug concentrations protective of HIV infection could streamline the development of chemoprevention strategies. Tissue models are promising, but limited concentration targets exist, and no systematic comparison to cell models or clinical studies has been performed. Design—We explored efficacy of maraviroc (MVC) and tenofovir (TFV) for HIV prevention by comparing Emax models from TZM-bl cells to vaginal tissue explants, and evaluated their predictive capabilities with a dose-challenge clinical study. Methods—HIV-1JR-CSF was utilized for viral challenge. Drug efficacy was assessed using a luciferase reporter assay in TZM-bl cells and real-time PCR to quantify spliced RNA in a tissue explant model.
    [Show full text]
  • This Project Has Been Supported with Unrestriced Grants from Abbvie Gilead Sciences HEXAL Janssen-Cilag MSD Viiv Healthcare By
    This project has been supported with unrestriced grants from AbbVie Gilead Sciences HEXAL Janssen-Cilag MSD ViiV Healthcare By Marcus Altfeld, Hamburg/Boston (USA) Achim Barmeyer, Dortmund Georg Behrens, Hannover Dirk Berzow, Hamburg Christoph Boesecke, Bonn Patrick Braun, Aachen Thomas Buhk, Hamburg Rob Camp, Barcelona (Spain/USA) Rika Draenert, Munich Christian Eggers, Linz (Austria) Stefan Esser, Essen Gerd Fätkenheuer, Cologne Gunar Günther, Windhoek (Namibia) Thomas Harrer, Erlangen Christian Herzmann, Borstel Christian Hoffmann, Hamburg Heinz-August Horst, Kiel Martin Hower, Dortmund Christoph Lange, Borstel Thore Lorenzen, Hamburg Tim Niehues, Krefeld Christian Noah, Hamburg Ramona Pauli, Munich Ansgar Rieke, Koblenz Jürgen Kurt Rockstroh, Bonn Thorsten Rosenkranz, Hamburg Bernhard Schaaf, Dortmund Ulrike Sonnenberg-Schwan, Munich Christoph D. Spinner, Munich Thomas Splettstoesser (Figures), Berlin Matthias Stoll, Hannover Hendrik Streeck, Essen/Boston (USA) Jan Thoden, Freiburg Markus Unnewehr, Dortmund Mechthild Vocks-Hauck, Berlin Jan-Christian Wasmuth, Bonn Michael Weigel, Schweinfurt Thomas Weitzel, Santiago (Chile) Eva Wolf, Munich HIV 2015/16 www.hivbook.com Edited by Christian Hoffmann and Jürgen K. Rockstroh Medizin Fokus Verlag IV Christian Hoffmann, M.D., Ph.D. ICH Stadtmitte (Infektionsmedizinisches Centrum Hamburg) Glockengiesserwall 1 20095 Hamburg, Germany Phone: + 49 40 2800 4200 Fax: + 49 40 2800 42020 [email protected] Jürgen K. Rockstroh, M.D., Ph.D. Department of Medicine I University of Bonn Sigmund-Freud-Strasse 25 53105 Bonn, Germany Phone: + 49 228 287 6558 Fax: + 49 228 287 5034 [email protected] HIV Medicine is an ever-changing field. The editors and authors of HIV 2015/16 have made every effort to provide information that is accurate and complete as of the date of publication.
    [Show full text]
  • Identification of a Novel Type of Small Molecule Inhibitor Against HIV-1
    BMB Rep. 2015; 48(2): 121-126 BMB www.bmbreports.org Reports Identification of a novel type of small molecule inhibitor against HIV-1 Byung Soo Kim1,#, Jung Ae Park1#,, Min-Jung Kim1, Seon Hee Kim2, Kyung Lee Yu2, & Ji Chang You1,2,* 1Avixgen Inc., 2National Research Laboratory of Molecular Virology, Department of Pathology, School of Medicine, The Catholic University of Korea, Seoul 137-701, Korea Here we report a new chemical inhibitor against HIV-1 with a anti-HIV-1 drugs targets the HIV-1 protease (2). Additionally, a novel structure and mode of action. The inhibitor, designated class of recently developed inhibitors blocks the activity of in- as A1836, inhibited HIV-1 replication and virus production tegrase, a viral enzyme required for the integration of the with a 50% inhibitory concentration (IC50) of 2.0 μM in an HIV-1 proviral DNA into the host DNA (3). Inhibitors of MT-4 cell-based and cytopathic protection antiviral assay, while non-enzymatic targets, which inhibit the viral entry process ei- its 50% cytotoxic concentration (CC50) was much higher than ther by blocking viral fusion or by acting as an antagonist 50 μM. Examination of the effect of A1836 on in vitro HIV-1 against the host cell receptor CCR5 comprise an additional reverse transcriptase (RT) and integrase showed that neither drug class (4). For the treatment of patients with HIV/AIDS, a were molecular targets of A1836. The characterization and so-called "HAART" (Highly Active AntiRetroviral Therapy) reg- re-infection assay of the HIV-1 virions generated in the pres- imen, which consists of a combination of three or four differ- ence of A1836 showed that the synthesis of early RT products ent approved drugs, is being used currently due to the rapid in the cells infected with the virions was inhibited dose-de- emergence of single drug treatment regimen-resistant strains pendently, due in part to abnormal protein formation within (5, 6).
    [Show full text]
  • Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis
    Review Article Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis Debajit Dey and Manidipa Banerjee* Kusuma School of Biological Sciences, Indian Institute of Technology Delhi, Hauz Khas, New Delhi, India Abstract When such inflammation, as manifested in symptoms such as jaundice, nausea, abdominal pain, malaise etc, is caused Viral hepatitis remains a significant worldwide threat, in spite by viral infections, the condition is referred to as viral hepatitis.1 of the availability of several successful therapeutic and vacci- Five hepatotropic viruses – named hepatitis A, B, C, D and nation strategies. Complications associated with acute and E viruses – target liver cells in humans and cause acute and chronic infections, such as liver failure, cirrhosis and hepato- chronic hepatitis. In addition, other viruses such as the cellular carcinoma, are the cause of considerable morbidity adenovirus, cytomegalovirus (CMV) and Epstein-Barr virus and mortality. Given the significant burden on the healthcare (EBV), occasionally cause symptoms of hepatitis.2 system caused by viral hepatitis, it is essential that novel, While an acute infection in healthy, immunocompetent more effective therapeutics be developed. The present review individuals is cleared spontaneously, complications like cir- attempts to summarize the current treatments against viral rhosis, hepatocellular carcinoma (HCC) and fulminant hepatic hepatitis, and provides an outline for upcoming, promising failure (FHF) may arise in immunocompromised individuals, new therapeutics. Development of novel therapeutics requires due to associated secondary reasons such as existing infec- an understanding of the viral life cycles and viral effectors in tions, alcohol abuse, or genetic predisposition.1,3 HCC, the molecular detail. As such, this review also discusses virally- third leading cause of cancer-related deaths worldwide,4 is encoded effectors, found to be essential for virus survival closely associated with hepatitis B virus (HBV) infections.
    [Show full text]
  • 24 March 2011 (24.03.2011) W O 201 1 /03 523 1 a 1
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau „ (10) International Publication Number (43) International Publication Date 24 March 2011 (24.03.2011) W O 201 1 /03 523 1 A 1 (51) International Patent Classification: (74) Agents: WARD, John et al.; Gilead Sciences, Inc., 333 C07D 487/04 (2006.01) Lakeside Drive, Foster City, CA 94404 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US20 10/049471 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (22) International Filing Date: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, 20 September 2010 (20.09.2010) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (26) Publication Langi English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (30) Priority Data: NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, 61/244,297 2 1 September 2009 (21 .09.2009) US SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant (for all designated States except US): GILEAD SCIENCES, INC. [US/US]; 333 Lakeside (84) Designated States (unless otherwise indicated, for every Drive, Foster City, CA 94404 (US).
    [Show full text]
  • Current and Future Therapies for Hepatitis C Virus Infection: from Viral Proteins to Host Targets
    Arch Virol DOI 10.1007/s00705-013-1803-7 BRIEF REVIEW Current and future therapies for hepatitis C virus infection: from viral proteins to host targets Muhammad Imran • Sobia Manzoor • Nasir Mahmood Khattak • Madiha Khalid • Qazi Laeeque Ahmed • Fahed Parvaiz • Muqddas Tariq • Javed Ashraf • Waseem Ashraf • Sikandar Azam • Muhammad Ashraf Received: 27 February 2013 / Accepted: 19 June 2013 Ó Springer-Verlag Wien 2013 Abstract Hepatitis C virus (HCV) infection is the most cell-targeting compounds, the most hopeful results have important problem across the world. It causes acute and been demonstrated by cyclophilin inhibitors. The current chronic liver infection. Different approaches are in use to SOC treatment of HCV infection is Peg-interferon, riba- inhibit HCV infection, including small organic compounds, virin and protease inhibitors (boceprevir or telaprevir). The siRNA, shRNA and peptide inhibitors. This review article future treatment of this life-threatening disease must summarizes the current and future therapies for HCV involve combinations of therapies hitting multiple targets infection. PubMed and Google Scholar were searched for of HCV and host factors. It is strongly expected that the articles published in English to give an insight into the near future, treatment of HCV infection will be a combi- current inhibitors against this life-threatening virus. HCV nation of direct-acting agents (DAA) without the involve- NS3/4A protease inhibitors and nucleoside/nucleotide ment of interferon to eliminate its side effects. inhibitors of NS5B polymerase are presently in the most progressive stage of clinical development, but they are linked with the development of resistance and viral Introduction breakthrough. Boceprevir and telaprevir are the two most important protease inhibitors that have been approved HCV is a major health burden affecting about 200 million recently for the treatment of HCV infection.
    [Show full text]
  • Inhibition of HIV-1 Replication by a Novel Acylguanidine-Based Molecule
    Inhibition of HIV-1 Replication by a Novel Acylguanidine-based Molecule Philip Mwimanzi1, Ian Tietjen2, Aniqa Shahid1, Scott C. Miller2, David Fedida2, Zabrina Brumme1,3, Mark A Brockman1,3,4 1Faculty of Health Sciences Simon Fraser Univ; 2Dept of Anesthesiology, Pharmacology and Therapeutics, Univ of British Columbia; 3BC Centre for Excellence in HIV/AIDS; 4Dept of Molecular Biology and Biochemistry, Simon Fraser Univ Background and Objec;ve SM111 inhibits in vitro HIV-1 replica;on SM111-selected muta;ons impair Vpu-mediated Tetherin and CD4 down regulaon, 60 and confer decreased suscep;bility to SM111 SM111 Recent advances in HIV-1 an1retroviral therapy (ART) have substan1ally reduced morbidity and B 60 A C SM113 Uninfected WT-NL43 ΔVpu-NL43 4 4 50 A 104 10 10 B 60 mfi:400 mortality, but the selec1on and transmission of drug-resistant strains necessitates ongoing 40 SM111 mfi:149 mfi:622 100 CD4 3 3 40 SM113 103 10 10 CD317 (Tetherin) discovery of new an1viral drugs. HIV-1 accessory proteins, including Vpu, enhance viral replicaon NL43 (No drug) 40 2 2 20 102 10 10 and in vivo pathogenesis and thus may be arac1ve targets for new classes of an1viral drugs. 30 NL43 (100uM SM111) 40 100 CD4 1 1 101 10 10 CD317 (Tetherin) 20 50 0 0 0 0 % Infected% cellsDay - 6 10 10 10 20 0 1 2 3 4 0 1 2 3 4 Vpu promotes virion release by downregulang the host restric1on factor BST-2/Tetherin. Vpu is 20 100 101 102 103 104 10 10 10 10 10 10 10 10 10 10 % Infected cells 10 1uM % Infected% cellsDay - 6 10uM 50 also reported to be a viroporin (i.e.
    [Show full text]
  • 2017 Post-EASL Report the INTERNATIONAL LIVER CONGRESS AMSTERDAM, NETHERLANDS • APRIL 19-23, 2017 Cover Page, Paste Image Over Entire Page
    EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 2017 Post-EASL Report THE INTERNATIONAL LIVER CONGRESS AMSTERDAM, NETHERLANDS • APRIL 19-23, 2017 Cover page, paste image over entire page 2017 Post-EASL Report May 2017 / 1 2017 Post-EASL Report Summary As chronic hepatitis C virus (HCV) drug development approaches the end-game following the launch of the first pan-genotypic regimen, Epclusa (sofosbuvir/velpatasvir; Gilead), recent and upcoming advances in chronic hepatitis B virus (HBV) treatment emerged as an important focus of The International Liver Conference (ILC) 2017, the annual meeting of the European Association for the Study of the Liver (EASL), which took place in Amsterdam, the Netherlands, on 19–23 April 2017. Particular interest was paid to 96- week safety data from pivotal studies of Vemlidy (tenofovir alafenamide [TAF]; Gilead), which Gilead hopes will drive its uptake in the face of imminent competition from generic versions of Viread (tenofovir disoproxil fumarate [TDF]; Gilead). Updated EASL guidelines for the management and treatment of chronic HBV were also released, which included a novel recommendation for the use of Vemlidy as a first- line agent in select patients, as well as a revised nomenclature for classifying the stages of chronic HBV infection. There was also considerable optimism regarding the potential of new modes of action in early-phase development for the treatment of HBV to improve upon the disappointingly low rates of hepatitis B surface antigen (HBsAg) loss observed after treatment with currently available therapies. While there are very limited efficacy data available for early-phase approaches, there was consensus during panel discussions of available data that combining currently approved nucleos(t)ide analogs (NAs) with novel agents, such as RNA interference, capsid assembly inhibitors, nucleic acid polymers, and immunostimulatory agents, represents a promising approach towards achieving “functional cure”.
    [Show full text]
  • Full PDF of 2013 Pipeline Report
    ABOUT HIV i-BASE HIV i-Base is a London-based HIV treatment activist organization. HIV i-Base works in the United Kingdom and internationally to ensure that people living with HIV are actively engaged in their own treatment and medical care and are included in policy discussions about HIV treatment recommendations and access. www.i-base.info ABOUT TAG The Treatment Action Group (TAG) is an independent AIDS research and policy think tank fighting for better treatment, a vaccine, and a cure for AIDS. TAG works to ensure that all people with HIV receive lifesaving treatment, care, and information. www.treatmentactiongroup.org 2013 PIPELINE REPORT HIV, HEPATITIS C VIRUS (HCV), AND TUBERCULOSIS (TB) DRUGS, DIAGNOSTICS, VACCINES, PREVENTIVE TECHNOLOGIES, RESEARCH TOWARD A CURE, AND IMMUNE-BASED AND GENE THERAPIES IN DEVELOPMENT By Polly Clayden, Simon Collins, Colleen Daniels, Mike Frick, Mark Harrington, Tim Horn, Richard Jefferys, Karyn Kaplan, Erica Lessem, and Tracy Swan Edited by Andrea Benzacar JUNE 2013 HIV i-BASE/TREATMENT AcTION GROUP AUTHORS Polly Clayden, Simon Collins, Colleen Daniels, Mike Frick, Mark Harrington, Tim Horn, Richard Jefferys, Karyn Kaplan, Erica Lessem, and Tracy Swan EXECUTIVE EDITOR Andrea Benzacar EDITORS Tim Horn and Scott Morgan DESIGNER Lei Chou ACKNOWLEDGMENTS i-Base thanks the Monument Trust and UNITAID for support for this work. Thanks to the TAG staff, board, and donors for supporting the production of the 2013 Pipeline Report. HIV i-Base Treatment Action Group 4th Floor, 57 Great Suffolk Street 261 Fifth
    [Show full text]
  • Antiretroviral Treatment Optimisation
    Fit for purpose Antiretroviral treatment optimisation HIV i-Base March 2020 ABOUT HIV i-BASE HIV i-Base is a London-based HIV treatment activist organisation. i-Base works in the United Kingdom and internationally to ensure that people living with HIV are actively engaged in their own treatment and medical care and are included in policy discussions about HIV treatment recommendations and access. www.i-base.info ABOUT FIT FOR PURPOSE i-Base’s annual Fit for Purpose summarises key developments in antiretroviral treatment optimisation for low- and middle-income countries. ABOUT HIV PIPELINE 2020: NEW DRUGS IN DEVELOPMENT i-Base produces an annual HIV pipeline review as a companion to Fit for Purpose. http://i-base.info/hiv-pipeline-report-march-2020 Contents Introduction . 3. Fit for purpose: antiretroviral treatment optimisation . 4 What does the World Health Organization recommend? 6 What we know and the evidence gaps 8 What is planned or ongoing? 26 What to watch out for at CROI 2020 and next steps 40 References 41 HIV pipeline 2020: new drugs in development . 52. Introduction: eight months since IAS 2019 53 Regulatory approvals and submissions 56 Compounds in development by class 58 Conclusion 71 References 73 Funded by Unitaid. HIV i-Base 107 The Maltings 169 Tower Bridge Road London SE1 3LJ Tel: +44 (0) 208 616 2210 www i-base info admin@i-base org uk An HTB South supplement ISSN 2046-9373 Design & typesetting: the earth is round, Cape Town, RSA 2 Fit for Purpose: Antiretroviral Treatment Optimisation – March 2020 Introduction HIV i-Base produces Fit for Purpose – a review of antiretroviral therapy (ART) optimisation – annually for distribution at the International AIDS Society (IAS) conferences, with updates to coincide with other key HIV meetings.
    [Show full text]
  • Advances in Antiretroviral Therapy Volume 15 Issue 2 April/May 2007
    Conference Highlights - Advances in Antiretroviral Therapy Volume 15 Issue 2 April/May 2007 Advances in Antiretroviral Therapy Joyce Jones, MD, Barbara Taylor, MD, Timothy J. Wilkin, MD, MPH, and Scott M. Hammer, MD The 14th Conference on Retroviruses and Opportunistic Infections provided line HIV-1 RNA of 4.8 to 4.9 log10 cop- a forum for presentation of state-of-the-art research on antiretroviral ies/mL. The primary endpoint, a reduc- therapy. This year’s conference marked the first public presentation of tion in plasma HIV-1 RNA at 24 weeks, phase III trials of the lead compounds in 2 new drug classes: maraviroc (a was statistically significantly greater in CCR5 inhibitor) and raltegravir (an HIV-1 integrase inhibitor). These agents the once-daily (1.82 log10 copies/mL) are likely to be approved by the US Food and Drug Administration this and twice-daily arms (1.95 log10 cop- year and should provide major new options for treatment-experienced ies/mL) than in the placebo arm (1.03 patients with multidrug resistant virus. Other dominant themes of the log10 copies/mL). Subjects in the once- conference were the impressive number of presentations describing and twice-daily arms were more likely outcomes of antiretroviral therapy programs in resource-limited settings to achieve plasma HIV-1 RNA levels and new information on mechanisms of drug resistance. Among the latter, below 50 copies/mL at week 24 than the importance of drug resistance mutations occurring in the RNase H and subjects in the placebo arm (42% and connection domains of the HIV-1 reverse transcriptase was of special note.
    [Show full text]